IMPAX LABORATORIES, INC. (NASDAQ:IPXL) Files An 8-K Entry into a Material Definitive AgreementItem 5.02 Entry into a Material Definitive Agreement.
|
ExhibitNo. |
Description |
| 2.1 | Amendment No.2 to the Business Combination Agreement, dated December16, 2017. |
| 10.1 | Employment Agreement dated as of December16, 2017 by and among Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and Robert A. Stewart. |
| 10.2 | Memorandum of Understanding dated as of December16, 2017 by and among Amneal Pharmaceuticals LLC, PaulM.Bisaro, Impax Laboratories, Inc. and Atlas Holdings, Inc. |
9
IMPAX LABORATORIES INC ExhibitEX-2.1 2 d491016dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 AMENDMENT NO. 2 TO THE BUSINESS COMBINATION AGREEMENT This AMENDMENT NO. 2 (this “Amendment”),…To view the full exhibit click here
About IMPAX LABORATORIES, INC. (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
